Skip to Main Content

Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s from Cassava Sciences.

The company said Thursday that a preliminary analysis of a small clinical trial showed its drug, called simufilam, improved the cognition of patients with Alzheimer’s disease — a benefit that no other treatment for Alzheimer’s has ever shown.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment